LONDON — In the year-plus since Najat Khan joined the AI-focused drug developer Recursion Pharmaceuticals, she has helped push forward — and prune — the company’s pipeline, and navigate its merger with Exscientia.
Now Khan, who was hired as Recursion’s chief commercial officer and R&D head, is set to take the reins as CEO in the new year.
Current CEO Chris Gibson, one of the founders of the company, announced earlier this month that he would step down, telling STAT that Recursion, which is moving toward later-stage development programs, needed a leader with a different skill set. Gibson is becoming board chair.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
